FDA Warns Providers Not to Use Any NECC Products

The FDA has warned healthcare providers to cease use of any products manufactured at the New England Compounding Center in Framingham, Mass., according to an AHA News Now report.

Advertisement

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

The alert comes after the FDA determined that two additional drugs, triamcinolone acetonide and cardioplegic solution, from the compounding center may be contaminated. A federal/state investigation is ongoing regarding contaminated steroid injections that led to an outbreak of meningitis, claiming 15 lives.

More Articles on Patient Safety:

7 Strategies for Collaboration and Safety in the Operating Room

8 Points of Survival for Surgery Centers After ACOs

Study: Simulation Training Needed to Boost Patient Safety, Operative Performance

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.